Bluebird Care has been acquired by Interim Healthcare Inc.
US-based care-at-home franchisor Interim Healthcare Inc. has acquired Bluebird Care, based in the UK, a national provider of care in the home. Financial details have not been provided.
Bluebird Care offers a unique service of tailored care visits from 30 minutes to full live-in support. The company has nearly 200 offices in the UK and the Republic of Ireland.
Founded in 1966, Interim Healthcare has more than 300 independently owned and operated franchise locations providing a variety of home health, senior care, hospice, palliative care, pediatric care and healthcare staffing services.
UK-based Oaklins Smith & Williamson, assisted by the team in Los Angeles, advised the seller in this transaction.


Talk to the deal team
Brian Livingston
Oaklins Evelyn Partners
Gary S. Rabishaw
Oaklins Intrepid
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more